

Carmel Ltd. – 2015 highlights

Carmel-Haifa University Economic Corporation Ltd. serves as the commercialization and business arm of the University and is responsible for protecting and commercializing its intellectual property. Carmel-Haifa collaborates with various partners and establishes ventures and funds with the goal of maximizing the business potential of commercializing research and knowledge developed at the University.

In the past year, Carmel invested in the cultivation of extensive business collaborations that led to major agreements. Carmel-Haifa continued to protect the intellectual property of the University and to realize its business potential. This year marked another great year in terms of income and fund raising.

The Carmel Innovations Investment Fund

The establishment of the **Carmel Innovations Investment Fund** is one of Carmel's major achievements. More than \$3 Million were invested in the Fund in two successful rounds, providing seed funding to companies established by Carmel for innovative projects led by researchers at the University.

Managed by Elka Nir, the **Carmel Innovations Investment Fund** provides seed funding to promising projects for approximately two years. The Fund invests up to \$700K in each startup and helps grow the companies to a stage where global companies or investors will participate in later investment rounds or acquire the company outright. The Fund's investors are joining the Fund's Board of Directors and the investment committee.

Participating in the Fund provides investors with the first right to select and invest in the most promising projects (large market, unmet need), which have already received significant support by the University and by foundations along the years. The investment in a portfolio of several companies mitigates risk for the investors. Carmel has developed special favorable vehicles for participating in the Fund.

Elka Nir, CEO, Carmel Ltd. & Carmel Innovations


25 years of experience in senior leadership positions:

Chairperson and board member of several public and private global companies.

Board member of IATI – **Israel Advanced Technology Industries** association.

Formerly:

Partner & Managing Director, **Giza Venture Capital**, leading investments and business successes; COO and VP Development at Biosense Webster, **Johnson & Johnson**; VP, R&D and VP Marketing & Sales at **General Electric (GE) Healthcare**



In addition to funding, Carmel Innovations provides to the established companies facilities, laboratories, management and marketing assistance. The Fund's management brings significant benefit to the startups with its extensive business network, experience in establishing strategic partnerships and access to governmental funding. Carmel gets equity in the startup companies and in the Fund.

New Ventures and Startup Companies

Carmel Innovations invested in 3 successful companies up to date - all established by Carmel based on University research. All three companies made good progress and one signed a significant agreement.

ArtsAvit Ltd.

Develops novel cancer medical treatment based on the cells' process of apoptosis (programmed cell death).
Based on Professor Sarit Larisch's research. The company made progress towards identifying a lead compound.

ResCure Ltd.

New therapeutic approach to treat recurring metastatic Cancer disease (specifically but not limited to Breast Cancer).
Based on the research of Dr. Dalit Barkan & Dr. Amiram Ariel.

Memofit Ltd. - **First Success! *Investment of NIS 8.1M by strategic global partners, ~7x valuation increase***

Alzheimer and MCI treatment based on research of Prof. Kobi Rozenblum. First success of the Fund (**see below**).

Carmel Innovations is in the process of investing in **two additional new startup companies:**

Memodero Ltd. - New drug for fear and anxiety disorders based on Dr. Rafi Lamprecht's research.

CanCure Ltd. - Cancer therapy based on mushroom derived compounds by Prof. Fuad Fares & Dr. Sharvit. Prof. Fares is a serial entrepreneur, among others was a founder of Prolor (PBTH: AMEX; TASE)

Carmel has raised additional significant funds for selected projects with commercial potential. In collaboration with the Division of External Relations, Carmel-Haifa raised \$600,000 to support Prof. Aaron Avivi's cancer research using the "resistant to cancer" blind mole rat as a laboratory model. (\$200,000 in 2015). In addition, Carmel signed a term sheet for an investment of \$400,000 in a startup company that will be based on the research of Prof. Avivi, Dr. Shames and Dr. Manov.

Carmel-Haifa also established a US-based company, Pine Biotech. The company develops applications based on the research activities of the Tauber Bioinformatics Center. The company has made nice progress and is collaborating with various partners globally.

Funding from the Office of Chief Scientist

In 2015, Carmel succeeded to triple the amount of funding for research programs from the Government (OCS) and next year we are expecting to cross the one Million NIS yearly support.

MemoFit Ltd. -

First success for the Carmel Innovations Fund

Within less than a year since inception, the company succeeded to raise: an investment of ~NIS 8.1M from :

Global strategic leading companies and a worldwide leading VC:

- **Significant *valuation increase: ~7x* within less than 1 year! , Great IRR**
- ***Strategic collaboration* with leading global pharma companies**
- **NIS 1.3M will be provided for research at the university**
- **In addition: Royalties based on revenues**

For More Information:

Elka Nir, CEO, Carmel

Elka @ELeadIN.com
Tel: +972-546-305-994